According to the Zhitong Financial APP, Genscript Bio (01548) rose by more than 6%, and as of the time of writing, it had risen by 6.01% to HKD 8.82 with a turnover of HKD 57.106 million.
Genscript bio announced that a milestone event for cilta-cel (currently marketed and sold in the United States under the brand name of CARVYKTI) has been reached in the development. Legend has received a total milestone payment of $380 million from Johnson & Johnson. In addition to the above, according to the cooperation agreement between Legend and Johnson & Johnson for cilta-cel, Legend has also received an additional milestone payment of $30 million. Cilta-cel is a chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA).
Bocom Intl previously stated that Johnson & Johnson's 1Q24 report showed that Carvykti recorded $157 million in sales, a year-on-year increase of 118.1%. In April 2024, Carvykti was approved in the United States and Europe for the treatment of early relapsed RRMM patients (2-4L), becoming the first BCMA CAR-T approved for this indication. The bank expects that the approval of this new indication will significantly reduce product OOS and gradually release new production capacity, and sales are expected to climb rapidly from the second half of the year, quarter by quarter.